Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511574 | 0.91 | ROCK2 (0.49) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL3512621 | 0.83 | ROCK2 (0.58) | ROCK2ROCK1NAMPTATG4BEPHX2 | |
| SCHEMBL354453 | 0.83 | ROCK2 (0.54) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL353431 | 0.81 | ROCK2 (0.55) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL4795207 | 0.80 | ROCK2 (0.46) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL885465 | 0.80 | ROCK2 (0.53) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL885466 | 0.80 | ROCK2 (0.53) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL3508692 | 0.79 | ROCK2 (0.44) | ROCK2ROCK1NAMPTATG4BNPC1 | |
| SCHEMBL3512821 | 0.77 | ROCK2 (0.56) | ROCK2ROCK1NAMPTATG4BEPHX2 | |
| SCHEMBL4792455 | 0.77 | ROCK2 (0.48) | ROCK2ROCK1NAMPTATG4BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | claimed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | claimed |
| WO-2009015193-A1 | ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009015193-A1 | ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | TST, UMPS, UROD | ROCK2 4700/4885ROCK1 4658/4885NAMPT 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.